Indivior Q1 GAAP net income rises 89% to $89 million; revenue climbs 19% to $317 million

• Indivior posted Q1 2026 GAAP net income of $89 million, compared with $123 million in non-GAAP net income.
• Revenue rose 19% to $317 million.
• Adjusted EBITDA more than doubled to $164 million.
• SUBLOCADE net revenue climbed 32% to $232 million, driven by 20% dispense unit volume growth.
• Full-year 2026 guidance was raised to revenue of $1.22 billion-$1.29 billion and adjusted EBITDA of $620 million-$660 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-193925), on April 30, 2026, and is solely responsible for the information contained therein.